{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:53:30Z","timestamp":1791201210123,"version":"4.2.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12185-026-04203-4","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T02:04:05Z","timestamp":1775268245000},"page":"470-477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recent advances in CAR T and CAR NK cell therapy for AML"],"prefix":"10.1007","volume":"124","author":[{"given":"Makiko","family":"Suga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"4203_CR1","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/ajh.25162","volume":"93","author":"C Ganzel","year":"2018","unstructured":"Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience. Am J Hematol. 2018;93:1074\u201381.","journal-title":"Am J Hematol"},{"key":"4203_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/ajh.24246","volume":"91","author":"H Kantarjian","year":"2016","unstructured":"Kantarjian H. Acute myeloid leukemia--major progress over four decades and glimpses into the future. Am J Hematol. 2016;91:131\u201345.","journal-title":"Am J Hematol"},{"key":"4203_CR3","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025;100:860\u201391.","journal-title":"Am J Hematol"},{"key":"4203_CR4","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","volume":"28","author":"AGX Zeng","year":"2022","unstructured":"Zeng AGX, Bansal S, Jin L, Mitchell A, Chen WC, Abbas HA, et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat Med. 2022;28:1212\u201323.","journal-title":"Nat Med"},{"key":"4203_CR5","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6:e441.","journal-title":"Blood Cancer J"},{"key":"4203_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41408-023-00911-w","volume":"13","author":"NJ Short","year":"2023","unstructured":"Short NJ, Nguyen D, Ravandi F. Treatment of older adults with FLT3-mutated AML: emerging paradigms and the role of frontline FLT3 inhibitors. Blood Cancer J. 2023;13:142.","journal-title":"Blood Cancer J"},{"key":"4203_CR7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41375-024-02246-2","volume":"38","author":"H Fruchtman","year":"2024","unstructured":"Fruchtman H, Avigan ZM, Waksal JA, Brennan N, Mascarenhas JO. Management of isocitrate dehydrogenase 1\/2 mutated acute myeloid leukemia. Leukemia. 2024;38:927\u201335.","journal-title":"Leukemia"},{"key":"4203_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/2643-3230.BCD-24-0171","volume":"6","author":"H Goulart","year":"2025","unstructured":"Goulart H, Kantarjian H, Pemmaraju N, Daver N, DiNardo CD, Rausch CR, et al. Venetoclax-based combination regimens in acute Myeloid Leukemia. Blood Cancer Discov. 2025;6:23\u201337.","journal-title":"Blood Cancer Discov"},{"key":"4203_CR9","doi-asserted-by":"publisher","first-page":"e912","DOI":"10.1097\/HS9.0000000000000912","volume":"7","author":"AH Wei","year":"2023","unstructured":"Wei AH, Roberts AW. BCL2 inhibition: a new paradigm for the treatment of AML and beyond. Hemasphere. 2023;7:e912.","journal-title":"Hemasphere"},{"key":"4203_CR10","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1182\/blood.V120.21.1521.1521","volume":"120","author":"R Gurion","year":"2012","unstructured":"Gurion R, Gafter-Gvili A, Ram R, Vidal L, Raanani P, Shpilberg O. The role of anti-CD33 for the treatment of acute Myeloid Leukemia \u2013 systematic review and meta-analysis. Blood. 2012;120:1521.","journal-title":"Blood"},{"key":"4203_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00277-014-2218-6","volume":"94","author":"J Loke","year":"2015","unstructured":"Loke J, Khan JN, Wilson JS, Craddock C, Wheatley K. Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol. 2015;94:361\u201373.","journal-title":"Ann Hematol"},{"key":"4203_CR12","doi-asserted-by":"publisher","first-page":"659595","DOI":"10.3389\/fimmu.2021.659595","volume":"12","author":"J Loke","year":"2021","unstructured":"Loke J, Buka R, Craddock C. Allogeneic stem cell transplantation for acute myeloid leukemia: Who, when, and how? Front Immunol. 2021;12:659595.","journal-title":"Front Immunol"},{"key":"4203_CR13","doi-asserted-by":"crossref","unstructured":"Koreth J. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009; 301.","DOI":"10.1001\/jama.2009.813"},{"key":"4203_CR14","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1182\/blood.2024025705","volume":"145","author":"M Gooptu","year":"2025","unstructured":"Gooptu M, Murdock HM, Soiffer RJ. How I treat AML relapse after allogeneic HSCT. Blood. 2025;145:2128\u201337.","journal-title":"Blood"},{"key":"4203_CR15","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","volume":"28","author":"M Duval","year":"2010","unstructured":"Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28:3730\u20138.","journal-title":"J Clin Oncol"},{"key":"4203_CR16","doi-asserted-by":"publisher","first-page":"6475","DOI":"10.1158\/1078-0432.CCR-20-3134","volume":"26","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Schmid C, Labopin M, Beelen D, Wolfgang Blau I, Potter V, et al. Evaluation of trends and prognosis over time in patients with AML relapsing after allogeneic hematopoietic cell transplant reveals improved survival for young patients in recent years. Clin Cancer Res. 2020;26:6475\u201382.","journal-title":"Clin Cancer Res"},{"key":"4203_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2174\/2589977515666230220092125","volume":"15","author":"R Sharma","year":"2023","unstructured":"Sharma R, Suravarjhula L, Banerjee M, Kumar G, Kumar N. Chimeric antigen receptor T-cell therapy in cancer: a critical review. Curr Drug Res Rev. 2023;15:241\u201361.","journal-title":"Curr Drug Res Rev"},{"key":"4203_CR18","doi-asserted-by":"publisher","first-page":"797440","DOI":"10.3389\/fbioe.2022.797440","volume":"10","author":"A Alnefaie","year":"2022","unstructured":"Alnefaie A, Albogami S, Asiri Y, Ahmad T, Alotaibi SS, Al-Sanea MM, et al. Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions. Front Bioeng Biotechnol. 2022;10:797440.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"4203_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","volume":"13","author":"R Huang","year":"2020","unstructured":"Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13(1):86.","journal-title":"J Hematol Oncol"},{"key":"4203_CR20","doi-asserted-by":"publisher","first-page":"7844","DOI":"10.1002\/cam4.5551","volume":"12","author":"S Abbasi","year":"2023","unstructured":"Abbasi S, Totmaj MA, Abbasi M, Hajazimian S, Goleij P, Behroozi J, et al. Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies. Cancer Med. 2023;12:7844\u201358.","journal-title":"Cancer Med"},{"key":"4203_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64\u201373.","journal-title":"N Engl J Med"},{"key":"4203_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145\u201361.","journal-title":"Nat Rev Cancer"},{"key":"4203_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell Lymphoblastic Leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"4203_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell Lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"4203_CR25","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini MC, Hu Z-H, Curran K, Laetsch T, Locke F, Rouce R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4:5414\u201324.","journal-title":"Blood Adv"},{"key":"4203_CR26","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:1403\u201315.","journal-title":"Lancet Oncol"},{"key":"4203_CR27","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood.2024024063","volume":"145","author":"S Haubner","year":"2025","unstructured":"Haubner S, Subklewe M, Sadelain M. Honing CAR T cells to tackle acute myeloid leukemia. Blood. 2025;145:1113\u201325.","journal-title":"Blood"},{"key":"4203_CR28","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41375-024-02351-2","volume":"38","author":"D Atar","year":"2024","unstructured":"Atar D, Ruoff L, Mast AS, Krost S, Moustafa-Oglou M, Scheuermann S, et al. Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia. Leukemia. 2024;38:2183\u201395.","journal-title":"Leukemia"},{"key":"4203_CR29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s12185-024-03809-w","volume":"120","author":"S Saito","year":"2024","unstructured":"Saito S, Nakazawa Y. CAR-T cell therapy in AML: recent progress and future perspectives. Int J Hematol. 2024;120:455\u201366.","journal-title":"Int J Hematol"},{"key":"4203_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.blre.2014.04.001","volume":"28","author":"GS Laszlo","year":"2014","unstructured":"Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014;28:143\u201353.","journal-title":"Blood Rev"},{"key":"4203_CR31","doi-asserted-by":"publisher","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","volume":"119","author":"RB Walter","year":"2012","unstructured":"Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119:6198\u2013208.","journal-title":"Blood"},{"key":"4203_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.exphem.2017.06.007","volume":"54","author":"AA Laing","year":"2017","unstructured":"Laing AA, Harrison CJ, Gibson BES, Keeshan K. Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia. Exp Hematol. 2017;54:40\u201350.","journal-title":"Exp Hematol"},{"key":"4203_CR33","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","volume":"35","author":"FP Tambaro","year":"2021","unstructured":"Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, et al. Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia. 2021;35:3282\u20136.","journal-title":"Leukemia"},{"key":"4203_CR34","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell. 2018;173:1439-53.e19.","journal-title":"Cell"},{"key":"4203_CR35","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/ijc.33865","volume":"150","author":"Y Liu","year":"2022","unstructured":"Liu Y, Wang S, Schubert ML, Lauk A, Yao H, Blank MF, et al. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int J Cancer. 2022;150:1141\u201355.","journal-title":"Int J Cancer"},{"key":"4203_CR36","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","volume":"14","author":"CT Jordan","year":"2000","unstructured":"Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stems cells. Leukemia. 2000;14:1777\u201384.","journal-title":"Leukemia"},{"key":"4203_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12113087","volume":"12","author":"H El Achi","year":"2020","unstructured":"El Achi H, Dupont E, Paul S, Khoury JD. CD123 as a biomarker in hematolymphoid malignancies: principles of detection and targeted therapies. Cancers (Basel). 2020;12:1\u201321.","journal-title":"Cancers (Basel)"},{"key":"4203_CR38","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","volume":"122","author":"A Mardiros","year":"2013","unstructured":"Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122:3138\u201348.","journal-title":"Blood"},{"key":"4203_CR39","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.2147\/OTT.S205678","volume":"12","author":"Y Sun","year":"2019","unstructured":"Sun Y, Wang S, Zhao L, Zhang B, Chen H. IFN-\u03b3 and TNF-\u03b1 aggravate endothelial damage caused by CD123-targeted CAR T cell. Onco Targets Ther. 2019;12:4907\u201325.","journal-title":"Onco Targets Ther"},{"key":"4203_CR40","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1182\/blood.2020009759","volume":"137","author":"M Wermke","year":"2021","unstructured":"Wermke M, Kraus S, Ehninger A, Bargou RC, Goebeler ME, Middeke JM, et al. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML. Blood. 2021;137:3145\u20138.","journal-title":"Blood"},{"key":"4203_CR41","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1182\/blood-2022-168877","volume":"140","author":"G Ehninger","year":"2022","unstructured":"Ehninger G, Kraus S, Sala E, Metzelder SK, Vucinic V, Fiedler W. Phase 1 dose escalation study of the rapidly switchable universal CAR-T therapy UniCAR-T-CD123 in relapsed\/refractory AML. Blood. 2022;140:2367\u20138.","journal-title":"Blood"},{"key":"4203_CR42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177867","author":"M Wermke","year":"2023","unstructured":"Wermke M, Metzelder S, Kraus S, Sala E, Vucinic V, Fiedler W. Updated results from a phase I dose escalation study of the rapidly-switchable universal CAR-T therapy UniCAR-T-CD123 in relapsed\/refractory AML. Blood. 2023. https:\/\/doi.org\/10.1182\/blood-2023-177867.","journal-title":"Blood"},{"key":"4203_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.blre.2018.10.003","volume":"34","author":"LM Morsink","year":"2019","unstructured":"Morsink LM, Walter RB, Ossenkoppele GJ. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. Blood Rev. 2019;34:26\u201333.","journal-title":"Blood Rev"},{"key":"4203_CR44","doi-asserted-by":"publisher","first-page":"6643948","DOI":"10.1155\/2021\/6643948","volume":"2021","author":"J Wang","year":"2021","unstructured":"Wang J, Wang W, Chen H, Li W, Huang T, Zhang W, et al. C-Type Lectin-Like Molecule-1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study. Biomed Res Int. 2021;2021:6643948.","journal-title":"Biomed Res Int"},{"key":"4203_CR45","doi-asserted-by":"publisher","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","volume":"64","author":"AB Bakker","year":"2004","unstructured":"Bakker AB, van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA, et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004;64:8443\u201350.","journal-title":"Cancer Res"},{"key":"4203_CR46","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1111\/jcmm.13519","volume":"22","author":"M Bill","year":"2018","unstructured":"Bill M, van Kooten Niekerk BP, Woll SP, Laine Herborg L, Stidsholt Roug A, Hokland P, et al. Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology. J Cell Mol Med. 2018;22:2311\u20138.","journal-title":"J Cell Mol Med"},{"key":"4203_CR47","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1080\/10428194.2022.2064986","volume":"63","author":"Q Li","year":"2022","unstructured":"Li Q, Liang C, Xu X, Zhang C, Cao W, Wang M, et al. CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia. Leuk Lymphoma. 2022;63:2136\u201348.","journal-title":"Leuk Lymphoma"},{"key":"4203_CR48","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","volume":"110","author":"A van Rhenen","year":"2007","unstructured":"van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110:2659\u201366.","journal-title":"Blood"},{"key":"4203_CR49","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","volume":"15","author":"X Jin","year":"2022","unstructured":"Jin X, Zhang M, Sun R, Lyu H, Xiao X, Zhang X, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J Hematol Oncol. 2022;15:88.","journal-title":"J Hematol Oncol"},{"key":"4203_CR50","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10:210.","journal-title":"Signal Transduct Target Ther"},{"key":"4203_CR51","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","volume":"2","author":"M Abou-El-Enein","year":"2021","unstructured":"Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, et al. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov. 2021;2:408\u201322.","journal-title":"Blood Cancer Discov"},{"key":"4203_CR52","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399.","journal-title":"Nat Rev Drug Discov"},{"key":"4203_CR53","doi-asserted-by":"crossref","unstructured":"Lonez C, Breman E. Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met? Cells. 2024; 13.","DOI":"10.3390\/cells13020146"},{"key":"4203_CR54","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","volume":"119","author":"H Torikai","year":"2012","unstructured":"Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119:5697\u2013705.","journal-title":"Blood"},{"key":"4203_CR55","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","volume":"75","author":"L Poirot","year":"2015","unstructured":"Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S, et al. Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies. Cancer Res. 2015;75:3853\u201364.","journal-title":"Cancer Res"},{"key":"4203_CR56","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","volume":"13","author":"S Jo","year":"2022","unstructured":"Jo S, Das S, Williams A, Chretien A-S, Pagliardini T, Le Roy A, et al. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing. Nat Commun. 2022;13:3453.","journal-title":"Nat Commun"},{"key":"4203_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117024","author":"M Bahramloo","year":"2024","unstructured":"Bahramloo M, Shahabi SA, Kalarestaghi H, Rafat A, Mazloumi Z, Samimifar A, et al. CAR-NK cell therapy in AML: Current treatment, challenges, and advantage. Biomed Pharmacother. 2024. https:\/\/doi.org\/10.1016\/j.biopha.2024.117024.","journal-title":"Biomed Pharmacother"},{"key":"4203_CR58","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331:44\u20139.","journal-title":"Science"},{"key":"4203_CR59","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1600-065X.2006.00451.x","volume":"214","author":"AG Freud","year":"2006","unstructured":"Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev. 2006;214:56\u201372.","journal-title":"Immunol Rev"},{"key":"4203_CR60","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","volume":"112","author":"MA Caligiuri","year":"2008","unstructured":"Caligiuri MA. Human natural killer cells. Blood. 2008;112:461\u20139.","journal-title":"Blood"},{"key":"4203_CR61","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bjh.17186","volume":"193","author":"H Rafei","year":"2021","unstructured":"Rafei H, Daher M, Rezvani K. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Br J Haematol. 2021;193:216\u201330.","journal-title":"Br J Haematol"},{"key":"4203_CR62","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1600-065X.2006.00455.x","volume":"214","author":"L Ruggeri","year":"2006","unstructured":"Ruggeri L, Aversa F, Martelli MF, Velardi A. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev. 2006;214:202\u201318.","journal-title":"Immunol Rev"},{"key":"4203_CR63","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fmed.2015.00093","volume":"2","author":"RS Mehta","year":"2016","unstructured":"Mehta RS, Shpall EJ, Rezvani K. Cord blood as a source of natural killer cells. Front Med. 2016;2:93.","journal-title":"Front Med"},{"issue":"1","key":"4203_CR64","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40364-022-00364-6","volume":"10","author":"L Zhang","year":"2022","unstructured":"Zhang L, Meng Y, Feng X, Han Z. CAR-NK cells for cancer immunotherapy: from bench to bedside. Biomark Res. 2022;10(1):12.","journal-title":"Biomark Res"},{"key":"4203_CR65","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32:520\u201331.","journal-title":"Leukemia"},{"key":"4203_CR66","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382:545\u201353.","journal-title":"N Engl J Med"},{"key":"4203_CR67","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30:772\u201384.","journal-title":"Nat Med"},{"key":"4203_CR68","first-page":"1083","volume":"8","author":"X Tang","year":"2018","unstructured":"Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu T, et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018;8:1083\u20139.","journal-title":"Am J Cancer Res"},{"key":"4203_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","volume":"14","author":"R Huang","year":"2025","unstructured":"Huang R, Wang X, Yan H, Tan X, Ma Y, Wang M, et al. Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial. Exp Hematol Oncol. 2025;14:1.","journal-title":"Exp Hematol Oncol"},{"key":"4203_CR70","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","volume":"15","author":"T Bexte","year":"2024","unstructured":"Bexte T, Albinger N, Al Ajami A, Wendel P, Buchinger L, Gessner A, et al. CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat Commun. 2024;15:8439.","journal-title":"Nat Commun"},{"key":"4203_CR71","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s43018-025-00934-1","volume":"6","author":"S Ikeda","year":"2025","unstructured":"Ikeda S, Hasegawa K, Kogue Y, Arimori T, Kawamoto R, Wibowo T, et al. CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant. Nat Cancer. 2025;6:595\u2013611.","journal-title":"Nat Cancer"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04203-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04203-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04203-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:02:22Z","timestamp":1791198142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04203-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4203"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04203-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.H. has applied for a patent entitled \u2018Antibody against acute myeloid leukemia\u2019 (PCT\/JP2023\/042029) through the Osaka University Office for University\u2013Industry Collaboration. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}